BMS 246 - Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.

The target population is SLE subjects between the ages of 18 and 75 with active moderate to severe disease. Diagnosed with Systemic Lupus Erythematosus (SLE) at least 24 weeks before the screening visit. On at least one immunosuppressant and/or antimalarial for 12 weeks or more prior to the screening visit, must be at a stable dose for 8 weeks or more before the screening visit, and must remain stable until randomization and throughout study participation.If on an oral corticosteroid (prednisone or equivalent), the dose must be stable for 2 weeks or more before the screening visit, and cannot exceed 30 mg/day at screening, and must remain stable until the Week 4 visit.